Skip to main content

Proceedings from the Workshop on Biomedical Materials at the Edge Challenges in the Convergence of Technologies (2006) / Chapter Skim
Currently Skimming:

Abstract: Context for New Biomedical Materials
Pages 13-17

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 14...
... Foote Division of Health Services Research and Policy University of Minnesota The process of making public policy can be characterized as follows: it classifies products, evolves over time, reflects political trends and opportunities, and works incrementally, not globally, to design appropriate regulations. The history of the U.S.
Read the entire page →
From page 15...
... The task force was asked to weigh new ideas and promote new ways to encourage innovation in health care and speed the development of effective new medical technologies, such as drug and biological products and medical devices. The task force was chaired by the FDA commissioner and included the heads of the CDC, the NIH, the National Cancer Institute, the AHCRQ, and the CMS.
Read the entire page →
From page 16...
... Some of the most challenging medical problems associated with chronic degenerative diseases include heart failure, arteriosclerosis, spine disease, and degenerative neurological disorders. Thus far, medical device companies have focused on electromechanical solutions to many of these problems.
Read the entire page →
From page 17...
... Examples of currently approved combination products include the use of recombinant human bone morphogenetic protein (Medtronic's INFUSETM) with spinal cages and continuous insulin delivery by a wearable pump (Medtronic's Paradigm®)
Read the entire page →

Key Terms

  • joint venture
  • medical technologies
  • potential risks
  • cell therapy
  • heart failure

  • biotechnology companies
  • combination products
  • medical technology
  • innovative medical
  • insurance business

  • challenging medical
  • liability insurance
  • medical devices
  • internal task
  • autologous skeletal

  • product submissions
  • spinal cages
  • biological product
  • diseases include
  • genzyme entered

  • approved combination
  • create products
  • core business
  • occurrence independent
  • design appropriate

  • bypass surgery
  • ischemic cardiomyopathies
  • political trends
  • policy values
  • synergistic research


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.